Herein, using CD19-specific CAR, our results indicate that IL-15 combined with IL-15Ra reduced the expression of CD132 compared to conventional CAR-T and IL-15 armored CAR-T cells, leading to the relatively highest survival rate and keeping liver healthier in tumor-treated mice. This evidence concerns the gene IL15 and neoplasm.